All In Biotech

Drug Trial Radar · NCT07846722

Esmolol Versus Dexmedetomidine for Opioid-sparing in Laparoscopic Gynecological Surgery

The Impact of Intraoperative Esmolol and Dexmedetomidine Administration on Opioid Consumption in Laparoscopic Gynecological Procedures: A Double-blinded Randomized Study

Last checked: Nov 20, 2026Latest source record: Sep 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

90

Planned (sponsor's estimate)

Start

Jul 15, 2026

Primary completion

Dec 1, 2026

Study completion Feb 1, 2027

Sponsor

Lead sponsor
Vasiliki SamartziAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Sep 29, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 20 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The aim of this study is to investigate and compare the effects of a continuous infusion of low-dose esmolol and dexmedetomidine versus placebo on intraoperative and postoperative opioid consumption and analgesic efficacy in patients undergoing laparoscopic hysterectomy.

Conditions

  • Pain, Acute Post-Operative
  • Dexmedetomidine
  • Analgesia
  • Esmolol
  • Nociceptive Pain
  • Laparoscopic Hysterectomy

Interventions

  • Esmolol hydrochlorideDrug

    In the esmolol group, patients will receive a loading dose of esmolol administered over 10 minutes in 100 mL of normal saline, followed by a continuous intraoperative esmolol infusion.

  • DexmedetomidineDrug

    In the dexmedetomidine group, patients will receive a loading dose of dexmedetomidine administered over 10 minutes in 100 mL of normal saline, followed by a continuous intraoperative dexmedetomidine infusion.

  • Normal (0.9%) salineDrug

    In the placebo group, patients will receive a loading dose of normal saline administered over 10 minutes in 100 mL of normal saline, followed by a continuous intraoperative normal saline infusion.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Total postoperative opioid consumptionTime frame: First 24 hours postoperatively
  2. PCA utilization parametersTime frame: First 24 hours postoperatively

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • "Alexandra" General Hospital

    Athens, Greece · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.